Professional outlooks on ACB are mixed, balancing its medical leadership against broader sector risks.
: While adjusted EBITDA reached $18.5 million , Aurora still reported a net loss of $51.6 million in Q3 2026, driven by costs rather than top-line movement alone. buy acb stock
: The company maintains a "cannabis debt-free" balance sheet with $154.4 million in cash as of December 31, 2025. Professional outlooks on ACB are mixed, balancing its
: Global medical cannabis now accounts for 81% of total revenue and 95% of adjusted gross profit , with medical margins holding steady at 69% . Market Sentiment & Ratings Professional outlooks on ACB are mixed
Aurora has demonstrated improving operational metrics despite bottom-line volatility.
Should You Buy, Hold or Sell ACB Stock Post Q3 Earnings Release?